CTOs on the Move

Edge Mechanical Systems

www.edgemech.com

 
Edge Mechanical Systems is a Denver, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Terumo Aortic

Aortic solutions that address every segment of the aorta. #borntostandout

Summa Health

Summa Health is one of the largest integrated delivery systems in Ohio. Encompassing a network of hospitals, community health centers, a health plan, a physician-hospital organization, a multi-specialty physician organization, research and multiple foundations, Summa is nationally renowned for excellence in patient care and for exceptional approaches to healthcare delivery. Summa also is a founding partner of the BioInnovation Institute in Akron. For more information, visit www.summahealth.org. Summa Health is an Affirmative Action employer that promotes Equal Employment Opportunity and Diversity for all individuals. Women, veterans, members of minority groups, and individuals with disabilities are encouraged to apply.

Advanced Orthopedics of Oklahoma

At Advanced Orthopedics of Oklahoma, our specialty-trained orthopedic doctors and staff deliver the expert, compassionate care needed to heal, recover, and advance throughout Oklahoma in Tulsa, Claremore, Bixby, McAlester.

Dauntless Pharmaceuticals

Dauntless Pharmaceuticals, Inc is a San Diego, CA-based biopharmaceutical company. The traditional biotech company holds numerous assets at various stages of development, and its investors, management, labs, and staff collectively share interest in all company assets. In contrast, Dauntless uses a one-asset, one-company model.

Amolyt Pharma

Amolyt Pharma is building on its team`s established expertise in therapeutic peptides development to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases. Amolyt Pharma`s programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism. The collaborative Amolyt Pharma team is well-equipped for upcoming milestones and for the adoption of additional programs as made possible by its global network in the field of endocrinology and with support from a strong syndicate of international investors.